Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013)
Bristol Myers Squibb (CELG-RI) reported Liabilities from Discontinued Operations of 4931000000.0 for Q4 2013.
Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 4931000000.0 in Q4 2013.
- Liabilities from Discontinued Operations for Q4 2013 came in at 4931000000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was 4931000000.0 (changed N/A YoY), and the FY2013 annual result was 4931000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 4931000000.0 in Q4 2013 per CELG-RI's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 4931000000.0 in Q4 2013 and troughed at 4931000000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 4.93 Bn |
| Dec 31, 2013 | 4.93 Bn |